Dyne Therapeutics (DYN) Cash from Investing Activities (2019 - 2026)

Dyne Therapeutics' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$2.4 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 264.06% year-over-year to -$2.4 million; the TTM figure through Mar 2026 stood at -$32.6 million (down 43.11% YoY), while the FY2025 annual figure was -$28.8 million, up 85.91% from the prior year.
• Cash from Investing Activities was -$2.4 million for Q1 2026 at Dyne Therapeutics, down from $982000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $51.7 million in Q3 2022 to a low of -$179.8 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$3.8 million across 5 years, with a median of $6.8 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities soared 8285.96% in 2022, then sank 764.54% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $19.2 million in 2022, then soared by 36.18% to $26.2 million in 2023, then plunged by 161.12% to -$16.0 million in 2024, then surged by 106.13% to $982000.0 in 2025, then sank by 343.58% to -$2.4 million in 2026.
• The last three Cash from Investing Activities figures came in at -$2.4 million (Q1 2026), $982000.0 (Q4 2025), and -$38.0 million (Q3 2025), per Business Quant data.